(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 May 2014 (30.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/079878 A1

(51) International Patent Classification:
*C07K 14/47* (2006.01)

(21) International Application Number:
PCT/EP2013/074276

(22) International Filing Date:
20 November 2013 (20.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12193560.5 21 November 2012 (21.11.2012) EP
61/729,048 21 November 2012 (21.11.2012) US

(71) Applicant: **MERZ PHARMA GMBH & CO. KGAA** [DE/DE]; Eckenheimer Landstrasse 100, 60318 Frankfurt am Main (DE).

(72) Inventors: **EISELE, Karl-Heinz**; Parlamentsplatz 2b, 60385 Frankfurt am Main (DE). **FINK, Klaus**; Lindenallee 28, 50968 Köln (DE).

(74) Agent: **DICK, Alexander**; Herzog Fiesser & Partner, Patentanwälte, Dudenstrasse 46, 68167 Mannheim (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


**Published**:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MEANS AND METHODS FOR DETERMINATION OF BOTULINUM NEUROTOXIN BIOLOGICAL ACTIVITY

**Fig. 2**




| Name | Start | End |
|---|---|---|
| CMV Promoter | 1 | 688 |
| Syt2 | 772 | 1023 |
| SNAP25 | 1024 | 1362 |
| Tet-On 3G | 1363 | 2106 |
| SV40-PolyA Signal | 2106 | 2575 |
| Amp(R) | 4589 | 3729 |
| Neo(R) | 6796 | 6002 |

(57) Abstract: The present invention is concerned with means and methods for determining neurotoxin activity. Specifically, it relates to a polynucleotide encoding a fusion polypeptide comprising (i) a transcription factor domain and (ii) a cytoplasmic retention domain,separated by a linker comprising a neurotoxin cleavage site and to a fusion polypeptide encoded by the polynucleotide of the invention. Also contemplated is a vector comprising the polynucleotide of the invention and a host cell comprising the polynucleotide, vector or fusion polypeptide of the invention. Moreover, envisaged is a method for determining neurotoxin activity in a sample. In addition, the invention pertains to the use of the polynucleotide, vector, fusion polypeptide or host cell of the invention for determining neurotoxin activity in a sample. Finally, the invention relates to a kit for determining neurotoxin activity comprising the polynucleotide, vector, fusion polypeptide or host cell of the invention.

WO 2014/079878 A1